| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Active Biotech AB (publ) (F: BTPC)
BTPC Technical Analysis
1
| As on 22nd Nov 2024 BTPC STOCK Price closed @ 0.01 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BTPCSTOCK Price
| Open | 0.01 | Change | Price | % |
| High | 0.01 | 1 Day | N/A | N/A |
| Low | 0.01 | 1 Week | 0.00 | 0.00 |
| Close | 0.01 | 1 Month | 0.00 | 0.00 |
| Volume | N/A | 1 Year | 0.00 | 0.00 |
| 52 Week High 0.00 | 52 Week Low 0.00 | ||||
F Germany Most Active Stocks
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| BTPC Daily Charts |
BTPC Intraday Charts |
Whats New @ Bazaartrend |
BTPC Free Analysis |
|
|
BTPC Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
BTPC Forecast November 2024
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
BTPC Weekly Forecast
| 4th UP Forecast | 0.00 |
| 3rd UP Forecast | 0.00 |
| 2nd UP Forecast | 0.00 |
| 1st UP Forecast | 0.00 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | 0.00 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | 0.00 |
BTPC Forecast2024
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
Active Biotech AB (publ) ( F Germany Symbol : BTPC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BTPC Business Profile
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service